ArticleThe breast journal2026
Refining Sentinel Lymph Node Biopsy Decisions for Clinically Node-Negative Microinvasive DCIS.
Article in The breast journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Refining Sentinel Lymph Node Biopsy Decisions for Clinically Node-Negative Microinvasive DCIS.The breast journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundDuctal carcinoma in situ with microinvasion (DCISM), defined as invasion ≤ 1 mm, occurs in 5%-10% of DCIS cases. There is ongoing debate on whether DCISM should be managed as DCIS or as small invasive cancer. As treatments increasingly emphasize minimizing morbidity, efforts have focused on identifying low-risk patients who may safely forgo axillary surgery, including sentinel lymph node biopsy (SLNB). However, axillary management of DCISM remains unclear due to limited data. This study aims to identify preoperative predictors of upstaging to invasive carcinoma on final pathology to guide SLNB use.
methodsA retrospective chart review was conducted of women aged ≥ 19 years with confirmed or suspected DCISM on initial biopsy who were clinically node negative and treated at a tertiary center from 2013 to 2023. Fisher's exact test and Student's t-test were used for categorical and continuous variables, respectively. Univariate and multivariate analyses were performed to identify predictors of upstaging.
resultsA total of 61 women with DCISM on initial biopsy were identified. Of these, 40.9% (25/61) were upstaged to invasive carcinoma on final pathology. Among upstaged patients, 95% (19/20) underwent SLNB at the time of surgery, and 12.5% (3/24) had positive lymph nodes. Time from biopsy to surgery did not differ significantly between groups (p = 0.12). Preoperative predictors of upstaging included palpable mass (OR 9.0, 95% CI 2.38-44.98, p = 0.003), mass on mammogram (OR 12.86, 95% CI 1.95-255.34, p = 0.02), and mass with calcifications (OR 13.34, 95% CI 1.30-255.08, p = 0.047).
conclusionClinically node-negative DCISM patients without a palpable or mammographic mass (with or without calcifications) had a low risk of upstaging and lymph node involvement, suggesting that they may safely forgo SLNB. Identifying preoperative variables can guide risk stratifications and de-escalation of axillary surgery. Larger prospective studies are needed to further inform guidelines for DCISM management in diverse populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.